Insider Selling: Andreas Wicki Sells 30,000 Shares of Pacira Pharmaceuticals Stock (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) Director Andreas Wicki sold 30,000 shares of Pacira Pharmaceuticals stock on the open market in a transaction dated Monday, August 25th. The stock was sold at an average price of $108.07, for a total transaction of $3,242,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on PCRX shares. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $98.00 to $110.00 in a research note on Friday, August 1st. Separately, analysts at Canaccord Genuity raised their price target on shares of Pacira Pharmaceuticals to $114.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 1st. They now have a $109.00 price target on the stock, up previously from $86.00. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $104.68.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 0.54% on Wednesday, hitting $107.13. 233,689 shares of the company’s stock traded hands. Pacira Pharmaceuticals has a 52-week low of $36.02 and a 52-week high of $108.50. The stock has a 50-day moving average of $94.83 and a 200-day moving average of $80.34. The company’s market cap is $3.845 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.04 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.25. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $42.20 million. Pacira Pharmaceuticals’s revenue was up 175.2% compared to the same quarter last year. Analysts expect that Pacira Pharmaceuticals will post $0.23 EPS for the current fiscal year.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Receive News & Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.